Figure 1.

Disposition of MDRA VAP patients included in the analysis of the impact of levofloxacin/Colistin and levofloxacin/high dose ampicillin-sulbactam infusion

MDRA, multidrug-resistant Acinetobacter; VAP, ventilator associated pneumonia; CKD, chronic kidney disease; AKI, acute kidney injury; CPIS,clinical pulmonary infection score; ARDS, acute respiratory distress syndrome;